BBC
An official review of warnings regarding common medications linked to impulsive behaviors—such as sex and gambling addictions—has been initiated following an investigation by BBC News, which uncovered a discrepancy in drug leaflets.
The investigation highlighted serious repercussions from the side effects of a class of drugs utilized to manage Parkinson's, Restless Legs Syndrome (RLS), and other conditions, leading to significant economic challenges, marital breakdowns, criminal behavior, and, in some cases, suicide.
Research indicates that one in six patients with Parkinson's who are prescribed these medications experience impulse control disorders—clinical terminology for such behavioral anomalies. However, it was found that these side effects were described as "uncommon" in the informational leaflets for one of these drugs, implying a prevalence of fewer than 1 in 100 patients.
Upon review, the UK's drug safety regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), confirmed to the BBC that "an error has been identified," committing to amend the label to accurately reflect these side effects as "common."
In light of these findings, the MHRA has initiated a comprehensive review of warnings for all eight medications categorized as dopamine agonists.
Boehringer Ingelheim, the manufacturer behind Pramipexole—an identified Parkinson's drug with impulsive behavior labeled as "uncommon"—asserted that its leaflets received regulatory approval and emphasized its dedication to enhancing patient safety.
Although the duration for which this error has persisted remains unclear, the BBC identified its presence in a leaflet dating back to 2021, indicating a misrepresentation that may have misled patients for at least five years.
Layla Moran, MP and chair of the Health Select Committee, expressed a desire for accountability from the MHRA, suggesting that it should extend an apology to impacted families for the oversight.
"I can't even begin to imagine what they have endured—abuse, financial devastation, and everything we've uncovered—only to learn they could have been warned more effectively," stated Moran.
In the case of Jane Ryde, her husband developed an addiction to pornography and demanded sexual encounters multiple times daily after starting treatment with Pramipexole for Parkinson's. She was not informed of any potential side effects by healthcare professionals; however, upon reviewing the leaflets, she found their classification as "uncommon" somewhat reassuring.
Unfortunately, by the time she recognized the intensified sexual urges in her husband, he had already experienced significant relief from the physical symptoms of Parkinson's due to the medication. This led to nearly a decade of distress for Jane as she navigated her husband’s drastic behavioral changes while concealing them from their children.
At one point, she meticulously documented her husband's conduct to present to his consultant, yet she received minimal support for her own welfare and no guidance on potential adjustments to his medication.
Jane's husband passed away in 2021, and she reflected that the man she knew prior to his prescription would have been "horrified" by the changes in his behavior.
She emphasized the importance of informing patients and their families regarding the actual incidence of these side effects, deeming it a "major scandal" that the warnings in her husband’s medication leaflet were misleading.
"You must enter these situations with full awareness. Without adequate information, it's challenging to know what signs to look out for."
Jane is hopeful that correcting this information will prevent future patients and their families from experiencing similar distress.
Regrettably, many individuals who reached out to BBC over the past year failed to connect the impulsive behaviors with their prescribed medications, often resulting in devastating outcomes.
The BBC shared accounts of individuals who engaged in harmful gambling and shopping sprees, with losses totaling hundreds of thousands of pounds. Notably, one solicitor embezzled £600,000 from vulnerable clients to fund visits to sex workers and for online sexual services, in addition to purchasing antiques.
As a response to the investigation, the MHRA will review all dopamine agonists, which were prescribed over 1.5 million times in England in the past year alone. Aside from managing Parkinson's and RLS, these medications are also employed in treating pituitary gland tumors and certain mental health conditions.
The misclassification noted in the Pramipexole leaflets starkly contrasts findings from a pivotal study conducted in 2010, which was funded and partially designed by the drug's manufacturer. Rather than the less than 1% prevalence of impulse control disorders as suggested in the existing leaflets, the study found approximately 17% of patients taking dopamine agonists were affected.
Although some study participants were on alternative Parkinson's medications, the research indicated that 14% of individuals on a dopamine agonist alone developed an impulse control disorder. Similar figures are cited by Parkinson's UK (17%) and the NHS (15%).
Experts have observed that these side effects are often underreported due to the stigma accompanying the resulting behaviors.
While the documentation for Pramipexole mentions an "urge to behave in an unusual way" as "common," a detailed breakdown of impulse control disorders by specific behaviors is categorized as "uncommon" specifically for Parkinson's patients.
According to Valerie Voon, a neuropsychiatrist and co-author of the 2010 study, stating that these disorders affect fewer than 1% of patients in drug leaflets is an understatement. She asserted that even compulsive behaviors like gambling should be classified as "common."
The BBC has found notable variability in how different manufacturers present side effect likelihood in their drug leaflets. For instance, British company GSK refrains from specifying side effect frequency for its drug Ropinirole, as the MHRA states the data is solely based on individual case reports, rendering it inappropriate for calculating general likelihood.
In addition, for RLS, impulse control disorders attributed to Pramipexole are similarly labeled "uncommon," despite clinical guidelines indicating that these disorders affect between 6% and 17% of patients.
Dr. Andy Berkowski, a neurologist involved in crafting clinical guidelines for RLS in the US, described such inconsistencies as "extremely misleading" and voiced the significant implications for patient care, asserting that information regarding prevalence rates for impulsive behaviors should be prominently featured in all informational materials due to their potential to severely disrupt lives.
Another consultant neurologist, Dr. Guy Leschziner, stated that many RLS patients end up receiving dosages that surpass recommended limits since these medications might exacerbate the underlying condition over time. He noted that impulse control disorders are generally not prevalent at very low doses but can pose significant issues at higher doses.
Liberal Democrat MP Layla Moran insisted that the UK government should hold the MHRA accountable for its medication warnings, emphasizing, "When the MHRA makes such substantial errors with dire consequences for people's lives, the government must reevaluate this matter."
The MHRA confirmed to the BBC its commitment to "rectifying the disconnect" in warnings and affirmed that its extensive review of all dopamine agonist drugs would be guided by consultations with independent experts.
While no medication is devoid of risks, the MHRA recognized that these drugs have significantly improved the quality of life for many patients. They justified the classification of these side effects as "uncommon" for those with Restless Legs Syndrome, stating that the categorization was accurate.
The MHRA also urged both patients and healthcare professionals to report any suspected side effects from these medications to the Yellow Card scheme, which gathers reports of adverse drug experiences.
Boehringer Ingelheim stated that it adheres to international guidelines regarding side effect frequency and continues to ensure its leaflets reflect the most current scientific knowledge available. In their statement, they acknowledged receiving reports from individuals experiencing impulse control disorders after being prescribed dopamine agonists for Parkinson's or RLS symptoms and commended those who have bravely shared their experiences to raise awareness.
Share this story